Drug Profile


Alternative Names: EMD-387008

Latest Information Update: 22 Feb 2017

Price : $50

At a glance

  • Originator Merck KGaA
  • Developer Poxel
  • Class Amines; Antihyperglycaemics; Small molecules; Triazines
  • Mechanism of Action AMP activated protein kinase stimulants; Glucose modulators; Mitochondrial permeability transition pore inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Type 2 diabetes mellitus

Most Recent Events

  • 12 Dec 2016 Poxel initiates enrolment in a phase IIa trial for Type-2 diabetes mellitus (In volunteers) in Germany (EudraCT2016-003215-35)
  • 05 Dec 2016 Pharmacodynamics data from a preclinical trial in Type-2 diabetes mellitus released by Poxel
  • 01 Sep 2016 Poxel completes a phase I safety trial in Healthy volunteers in United Kingdom (PO, Tablet) (NCT02924337)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top